Relacorilant is a novel highly selective non-steroidal GR modulator, with ongoing phase III studies (NCT03697109, NCT04308590, and NCT04373265) after promising results shown in the phase II study on CS cases with glucose metabolism impairment and/or arterial hypertension. The gene discussed is NR3C1; the disease is Cowden syndrome 1.